Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Northstar Neuroscience

This article was originally published in The Gray Sheet

Executive Summary

Seattle firm announces completion of enrollment May 31 in the 174-patient, 21-center randomized pivotal trial of its Renova-ST cortical stimulation system for treatment of post-stroke motor recovery. The EVEREST trial compares improvement in hand and arm function in chronic stroke survivors treated with physical therapy alone versus those treated with physical therapy plus stimulation of the cerebral cortex with Renova-ST. Northstar hopes to file a PMA for the device by the end of 2007 (1"The Gray Sheet" July 31, 2006, p. 13)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel